HEALTH CARE RESOURCE UTILIZATION (HCRU) OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NIVOLUMAB VERSUS DOCETAXEL: RESULTS FROM THE CHECKMATE 078 (CM078) TRIAL

被引：0
|
作者：
Lawrance, R. [1 ]
DeRosa, M. [2 ]
Taylor, F. [2 ]
Penrod, J. R. [3 ]
Shaw, J. W. [4 ]
Wang, P. F. [5 ]
机构：
[1] Adelphi Values, Bollington SK10 5JB, Cheshire, England
[2] Adelphi Values, Boston, MA USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[5] BMS, Jamison, PR USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.247
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN123
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [41] Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)
    Zalcberg, JR
    Bishop, JF
    Millward, MJ
    Zimet, A
    Laird, J
    Barter, C
    Seward, D
    McKeage, MJ
    Friedlander, ML
    Toner, G
    Berille, J
    Blanc, C
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1084 - 1084
  • [42] Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
    Costantini, Adrien
    Julie, Catherine
    Dumenil, Coraline
    Helias-Rodzewicz, Zofia
    Dumoulin, Jennifer
    Giraud, Violaine
    Labrune, Sylvie
    Chinet, Thierry
    Emile, Jean-Francois
    Giroux-Leprieur, Etienne
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [43] Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea
    Cho, E. K.
    Kang, J. H.
    Han, J-Y.
    Lee, J. S.
    Kim, D-W.
    Kim, S-W.
    Min, Y. J.
    Lee, K. H.
    Kim, J-H.
    Park, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] Cobolimab With Dostarlimab and Docetaxel in Patients (pts) With Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
    Kim, Hye Ryun
    Gridelli, Cesare
    Kapur, Dinesh
    Tufman, Amanda
    Felip, Enriqueta
    Velcheti, Vamsidhar
    Kim, Yu Jung
    Goetze, Thorsten
    Lopez, Pilar Garrido
    Corre, Romain
    Penkov, Konstantin
    Anjum, Rana
    Di Pace, Brian
    Liu, Wenlei
    Borgovan, Theo
    Ledger, Danielle
    Carver, Jennifer
    Waszak, Angela
    Dhar, Arindam
    Novello, Silvia
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 163 - 163
  • [45] Measures of aggressive care in advanced non-small cell lung cancer (NSCLC) patients
    McCannon, J.
    Jackson, V. A.
    Billings, J. A.
    Pirl, W. F.
    Greer, J.
    Lynch, T. J.
    Temel, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in hemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC)
    Paz-Ares, L.
    Brahmer, J.
    Hellmann, M. D.
    Reck, M.
    O'Byrne, K.
    Borghaei, H.
    Geese, W. J.
    Lu, H.
    Nathan, F. E.
    Ramalingam, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab
    Cusato, Jessica
    Genova, Carlo
    Tomasello, Cristina
    Carrega, Paolo
    Ottonello, Selene
    Pietra, Gabriella
    Mingari, Maria Cristina
    Cossu, Irene
    Rijavec, Erika
    Leggieri, Anna
    Di Perri, Giovanni
    Dal Bello, Maria Giovanna
    Coco, Simona
    Boccardo, Simona
    Ferlazzo, Guido
    Grossi, Francesco
    D'Avolio, Antonio
    CANCERS, 2019, 11 (01):
  • [48] 18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results
    Polverari, G.
    Ambrosini, V.
    Gelsomino, F.
    Diodato, S.
    Ceci, F.
    Sperandi, F.
    Ardizzoni, A.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S305 - S305
  • [49] Docetaxel and Exisulind in previously treated non-small cell lung cancer (NSCLC) patients: A multicenter, phase II clinical trial
    Weiss, Glen J.
    Vokes, Everett E.
    Bunn, Paul A., Jr.
    Magree, Lyn
    Rusk, Jason
    Albert, Don
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (10) : 933 - 938
  • [50] Evaluation of disease-related symptoms in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) treated with nivolumab (NIVO) or docetaxel (DOC)
    Gralla, R. J.
    Coon, C.
    Taylor, F.
    Penrod, J. R.
    DeRosa, M.
    Dastani, H.
    Orsini, L.
    Reck, M.
    Oncology Research and Treatment, 2015, 38 : 14 - +
12345